Botanical

Arjuna

Terminalia arjuna

Terminalia arjuna bark appears in a PRISMA-guided systematic review and meta-analysis of Ayurvedic interventions for essential hypertension (44 studies; 10 RCTs pooled, 524 participants), most often within polyherbal formulations such as Arjuna vachadi yoga (1 g/day, 2 divided doses, 3 months) and an Arjuna-Gokshura powder combined with Virechana purification. Within these formulations, uncontrolled pre-post data showed large blood-pressure reductions (systolic -17.55 mmHg, p<0.001; diastolic -14.64 mmHg, p<0.001), but the review's own pooled controlled analysis across all Ayurvedic interventions found no significant blood-pressure benefit versus placebo (-2.63 mmHg systolic, p=0.13) or versus standard antihypertensive drugs (-0.22 mmHg, p=0.47) - a gap between encouraging single-arm formulation data and controlled trial evidence that the review itself highlights.

1

STUDY

2

STUDIED WITH

2

CONDITIONS

2

TRADITIONS

Studies about Arjuna in Akasha →

How it's used

Parts and preparations, and the conditions they're used for.

bark · powder (polyherbal formulation)hypertension · high blood pressure

These uses are flagged for review — traditional-use claims kept as reported, never as advice.

What the studies found

Findings backed by a source paper, not traditional use alone.

bark · powder (polyherbal formulation) — Within Arjuna vachadi yoga: pre-post SBP -17.55 mmHg (p<0.001), DBP -14.64 mmHg (p<0.001); uncontrolled single-arm evidence

Read the source study →

Studies about Arjuna

1 completed study · newest first

Effectiveness and safety of Ayurvedic intervention in essential hypertension: a systematic review with meta-analysis.

Saylee Deshmukh et al. (2025) · Frontiers in pharmacology

This systematic review and meta-analysis examined whether Ayurvedic treatments — herbs, traditional formulations, and purification procedures — can genuinely lower blood pressure in essential hypertension, the symptomless condition that drives much of the world's heart disease and stroke. Researchers screened over 22,000 records from six databases, including India's AYUSH Research Portal, and included 44 studies, with ten randomized controlled trials (524 participants) providing data strong enough to pool statistically. The interventions ranged widely: single herbs like Arjuna (Terminalia arjuna, Ayurveda's principal heart remedy), Rudraksha seed powder, and Eclipta alba extract; polyherbal and herbomineral formulations; and Panchakarma purification procedures such as therapeutic purgation. Treatment durations ran from 10 days to a full year. The meta-analysis compared Ayurveda against two benchmarks — placebo and standard blood-pressure drugs — using Cochrane methods with formal risk-of-bias assessment. The pooled answer was no significant difference either way. Versus placebo, systolic pressure fell a non-significant 2.63 mmHg (95% CI −6.04 to 0.79, p=0.13); versus standard drugs the gap was essentially zero (−0.22 mmHg, p=0.47) — Ayurveda neither beat the drugs nor clearly lost to them. Heterogeneity was extreme (I² up to 98%), meaning the trials disagreed sharply: two of three placebo-controlled and five of eight drug-controlled trials individually favored Ayurveda, while others favored the comparator. Uncontrolled before-after studies showed large drops of 16–29 mmHg, but those designs cannot separate treatment effects from regression to the mean. No adverse events were reported where safety was tracked. The honest takeaway on Ayurvedic care for high blood pressure: the tradition's safety record in these studies was good and some individual trials are promising, but pooled controlled evidence does not yet show blood-pressure reductions beyond placebo or medication. Given the risks of unmanaged hypertension, the review's own conclusion is that the evidence does not yet justify Ayurvedic approaches standing in for proven treatment.

Read summary →Full text available